Penumbra/$PEN
1D1W1MYTD1Y5YMAX
About Penumbra
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
- Ticker
- $PEN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 4,700
- Headquarters
- Alameda, United States
- Website
- www.penumbrainc.com
Penumbra Metrics
BasicAdvanced
$13B
79.94
$4.07
0.70
-
Price and volume
Market cap
$13B
Beta
0.7
52-week high
$362.41
52-week low
$221.26
Average daily volume
342K
Financial strength
Current ratio
5.75
Quick ratio
3.633
Long term debt to equity
12.8
Total debt to equity
13.896
Interest coverage (TTM)
144.22%
Profitability
EBITDA (TTM)
204.282
Gross margin (TTM)
67.84%
Net profit margin (TTM)
10.67%
Operating margin (TTM)
12.45%
Effective tax rate (TTM)
21.22%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
6.42%
Return on equity (TTM)
11.37%
Valuation
Price to earnings (TTM)
79.939
Price to revenue (TTM)
8.476
Price to book
8.37
Price to tangible book (TTM)
9.43
Price to free cash flow (TTM)
59.079
Free cash flow yield (TTM)
1.69%
Free cash flow per share (TTM)
5.504
Growth
Revenue change (TTM)
17.55%
Earnings per share change (TTM)
8.81%
3-year revenue growth (CAGR)
17.08%
10-year revenue growth (CAGR)
20.78%
3-year earnings per share growth (CAGR)
74.97%
10-year earnings per share growth (CAGR)
33.31%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Penumbra News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.